Results

• All
• Video
• Audio
• Images

• Most recent

1–4 of 4 results for MCO-010

• 

  Extended Efficacy and Safety of MCO-010 Optogenetic Therapy for RP: 126-Week Results From the RESTORE Follow-Up Study (REMAIN)

  David S Liao, MD, PhD

  Annual Meeting Talks

  2025

• 

  MCO-010 Optogenetic Therapy for Severe Vision Loss in Stargardt Disease: 6-Month Outcomes From the Phase 2 STARLIGHT Trial

  Allen C Ho, MD FASRS

  Annual Meeting Talks

  2023

• 

  BCVA Analysis of Low- or High-Dose MCO-010 Optogenetic Therapy for Retinitis Pigmentosa: FIRST TIME 100-Week TOPLINE Results From a Phase 2b/3 Clinical Trial (RESTORE)

  Michael A. Singer, MD

  Annual Meeting Talks

  2024

• 

  BVA Analysis of Low- or High-Dose MCO-010 Optogenetics Therapy for Retinitis Pigmentosa: First Time 100-Week TOPLINE Results From a Phase 2b/3 Clinical trial (RESTORE)

  Michael A. Singer, MD

  Updates from the Field

  2024